Non-Stimulant ADHD Medications — Atomoxetine, Guanfacine, Viloxazine & More

Non-stimulant medications are a class of drugs approved for treating attention-deficit/hyperactivity disorder (ADHD) that work through mechanisms different from traditional stimulants like methylphenidate (Ritalin) or amphetamine (Adderall). While stimulants primarily increase dopamine and norepinephrine activity through direct release or reuptake inhibition, non-stimulants typically target norepinephrine systems more selectively or act through alpha-2 adrenergic pathways.

The FDA has approved several non-stimulant medications for ADHD:

• Atomoxetine (Strattera) — a selective norepinephrine reuptake inhibitor (NRI)
• Guanfacine extended-release (Intuniv) — a selective alpha-2A adrenergic agonist
• Clonidine extended-release (Kapvay) — a non-selective alpha-2 adrenergic agonist
• Viloxazine extended-release (Qelbree) — a norepinephrine reuptake inhibitor with serotonin-modulating properties

Non-stimulants are generally considered second-line treatments because stimulants demonstrate higher average effect sizes in clinical trials. However, non-stimulants are preferred in certain clinical situations and may be the best option for many individuals.

Atomoxetine selectively blocks the norepinephrine transporter (NET) in the prefrontal cortex, increasing norepinephrine availability in brain regions critical for attention, working memory, and impulse control. Because NET also transports dopamine in the prefrontal cortex, atomoxetine indirectly increases prefrontal dopamine as well — without significantly affecting dopamine in the nucleus accumbens (the brain's reward center), which is why it has minimal abuse potential.

Guanfacine stimulates post-synaptic alpha-2A adrenergic receptors in the prefrontal cortex. These receptors strengthen the functional connectivity of prefrontal networks involved in attention, working memory, and behavioral regulation. Research by Amy Arnsten at Yale has shown that guanfacine directly strengthens "top-down" cognitive control by enhancing prefrontal cortical network connections.

Clonidine works similarly to guanfacine but is less selective for the alpha-2A subtype, binding to alpha-2A, 2B, and 2C receptors. This broader activity profile means it produces more sedation and is particularly useful for ADHD symptoms of hyperactivity and impulsivity, as well as co-occurring sleep difficulties.

Viloxazine, the newest FDA-approved non-stimulant (2021), primarily inhibits norepinephrine reuptake and also modulates serotonin receptors (acting as a 5-HT2B agonist and 5-HT7 antagonist). This dual mechanism may contribute to its efficacy for ADHD with co-occurring mood or anxiety symptoms.

Non-stimulant medications may be preferred or recommended in several clinical scenarios:

• Stimulant intolerance — individuals who experience significant side effects from stimulants such as severe appetite suppression, insomnia, anxiety, or mood changes
• Substance use history or risk — non-stimulants have no abuse potential and are not controlled substances
• Co-occurring anxiety — atomoxetine and viloxazine may help both ADHD and anxiety symptoms; stimulants sometimes worsen anxiety
• Co-occurring tic disorders — guanfacine and clonidine can improve both ADHD symptoms and tics
• Cardiac concerns — while all ADHD medications require cardiovascular monitoring, alpha-2 agonists generally lower blood pressure rather than raising it
• Need for 24-hour coverage — non-stimulants provide continuous symptom control, unlike stimulants that wear off
• Stimulant non-response — approximately 20-30% of individuals with ADHD do not respond adequately to stimulants

Non-stimulants can also be used as adjuncts to stimulants. The combination of a stimulant plus guanfacine or clonidine is a common strategy when stimulants alone provide incomplete symptom control.

Meta-analyses consistently show that non-stimulants are effective for ADHD but generally have smaller average effect sizes compared to stimulants:

• Atomoxetine: Effect size approximately 0.45-0.65 (moderate), compared to 0.8-1.0 for stimulants. About 50-60% of patients show meaningful improvement.
• Guanfacine ER: Effect size approximately 0.50-0.80 depending on the study. Particularly effective for hyperactivity-impulsivity symptoms.
• Viloxazine ER: Clinical trials demonstrated effect sizes of 0.45-0.55 in children and adolescents.
• Clonidine ER: Effect size approximately 0.30-0.45, often most beneficial as an adjunct to stimulants.

An important distinction: non-stimulants typically require 4-8 weeks to reach full therapeutic effect, whereas stimulants work within hours. This means the initial response to a non-stimulant may underrepresent its eventual efficacy, and patients should be counseled to continue treatment for at least 6-8 weeks before concluding it is ineffective.

The 2024 NICE guidelines and American Academy of Pediatrics guidelines both recommend stimulants as first-line pharmacotherapy for ADHD, with non-stimulants as appropriate second-line options or first-line choices when clinical factors favor them.

Each non-stimulant has a distinct side effect profile:

Atomoxetine:

• Nausea and decreased appetite (most common, often improves over weeks)
• Fatigue or sedation (usually transient)
• Dry mouth
• Urinary hesitancy in adults
• Increased heart rate and blood pressure (modest, typically 5-10 mmHg)
• Rare but serious: Hepatotoxicity (very rare, discontinue if jaundice or liver symptoms occur); FDA black box warning for suicidal ideation in children and adolescents (similar rate to SSRIs)

Guanfacine ER:

• Sedation and drowsiness (most common, usually dose-dependent and may improve)
• Decreased blood pressure and heart rate
• Headache
• Abdominal pain
• Important: Must be tapered gradually — abrupt discontinuation can cause rebound hypertension

Clonidine ER:

• Similar to guanfacine but generally more sedating
• Dry mouth
• Bradycardia
• Hypotension
• Important: Same rebound hypertension risk with abrupt discontinuation

Viloxazine ER:

• Nausea and vomiting (most common)
• Decreased appetite
• Insomnia or somnolence
• Headache
• FDA black box warning for suicidal ideation in children and adolescents

Non-stimulant medications are typically started at a low dose and gradually increased (titrated) over several weeks:

• Atomoxetine: Usually started at 0.5 mg/kg/day in children or 40 mg/day in adults, with target dose of 1.2-1.4 mg/kg/day. Full effects may take 4-6 weeks.
• Guanfacine ER: Typically started at 1 mg daily and increased by 1 mg per week, with target doses of 1-4 mg daily for children. Full effects at 3-5 weeks.
• Clonidine ER: Started at 0.1 mg daily at bedtime, titrated to 0.1-0.4 mg daily. Full effects at 3-5 weeks.
• Viloxazine ER: Started at 100 mg daily in children (6-11) or 200 mg in adolescents (12-17), titrated weekly. Full effects at 2-4 weeks.

Unlike stimulants, patients should not expect to notice effects on the first day. Benefits emerge gradually. It is important to maintain consistent daily dosing — skipping doses can reduce effectiveness and, for alpha-2 agonists, can cause rebound effects.

Your prescriber will likely schedule follow-up appointments at 2-4 week intervals initially to assess response, adjust dosing, and monitor for side effects. Baseline and periodic monitoring of heart rate, blood pressure, and weight is standard practice.

Cost is an important consideration, as it varies significantly among non-stimulants:

• Atomoxetine: Generic available since 2017, making it the most affordable option. Generic cost is typically $30-80/month with insurance or through discount programs.
• Guanfacine ER: Generic available. Cost is typically $20-60/month for generic.
• Clonidine ER: Generic available. Generally the most affordable option at $15-40/month.
• Viloxazine ER: Brand-name only (Qelbree). Without insurance, it can cost $300-400/month. Manufacturer copay assistance programs are available.

Because non-stimulants are not controlled substances, they offer practical advantages: prescriptions can include refills, can be called in by phone, and do not require monthly in-person visits in many states. This can reduce the burden of ADHD treatment significantly.

Most insurance plans cover at least one non-stimulant medication. Prior authorization may be required, particularly if a stimulant trial has not been attempted first. Your prescriber's office can assist with the prior authorization process.

If a non-stimulant alone provides insufficient symptom control, several evidence-based strategies may be considered:

• Combination therapy: Adding a low-dose stimulant during peak-demand hours while maintaining the non-stimulant for baseline coverage. Guanfacine or clonidine plus a stimulant is one of the most studied and commonly used combinations.
• Switching within class: Trying a different non-stimulant — mechanisms of action differ enough that response to one does not predict response to another.
• Behavioral interventions: Cognitive-behavioral therapy (CBT), organizational skills training, and behavioral parent training complement medication and may reduce the medication dose needed.
• Off-label options: Bupropion, modafinil, and tricyclic antidepressants are sometimes used off-label for ADHD when approved medications are ineffective or not tolerated.

Treatment decisions should be individualized based on symptom severity, comorbidities, prior treatment response, patient preferences, and practical factors like cost and scheduling.